August 2024
Novo Nordisk Unveils Enhanced Cardiovascular Benefits of Semaglutide in Post-Hoc Analysis
Semaglutide, Cardiovascular Outcomes, Obesity, Type 2 Diabetes, Novo Nordisk, Post-Hoc Analysis
FDA Approves Emergent’s ACAM2000 Vaccine for Mpox Prevention, Pledges 50,000 Doses to Affected Regions
FDA approval, Emergent BioSolutions, ACAM2000 vaccine, mpox prevention, vaccine donation, global health response
Alnylam’s Vutrisiran Shows Promise in ATTR-CM Treatment, but Faces Competition
Alnylam, Vutrisiran, ATTR-CM, Phase 3 Trial, HELIOS-B, RNAi Therapeutics, Cardiomyopathy, Amyloidosis
FDA Approves Revolutionary Re-Expandable Stent for Young Children
FDA approval, re-expandable stent, young children, congenital heart disease, minimally invasive procedures
Catalent Reports Strong Q4 Results Amid Pending Acquisition by Novo Holdings
Catalent, Q4 Results, Novo Holdings, Acquisition, Pharmaceutical, Biotech, Consumer Health
NuCana’s Chemotherapy Replacement Fails to Improve Survival in Phase II Trial
NuCana, chemotherapy replacement, Phase II trial, progression-free survival, colorectal cancer, NUC-3373
ReNeuron Exits London Stock Exchange Amid Jacobio’s China Rights Deal
ReNeuron, Jacobio, London Stock Exchange, AIM, China rights deal, biotech, stem cell therapy
QIAGEN and AstraZeneca Enhance Partnership to Develop Companion Diagnostics for Chronic Diseases
QIAGEN, AstraZeneca, companion diagnostics, chronic diseases, precision medicine, QIAstat-Dx, genotyping assay
BioMarin Announces Significant Workforce Reduction Amid Restructuring Efforts
BioMarin, layoffs, restructuring, biotech, rare diseases, gene therapy, Roctavian, hemophilia A
Launching a Product in Europe: Understanding Supply Chain Cost Drivers
Supply Chain Cost Analysis, European Market, Cost Drivers, Supply Chain Management, Risk Management